

CONTENTS

Platinum Opinions		The Platinum Hall of Fame http://dx.doi.10.1016/j.eururo.2019.07.028	e53
	Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?	265	
	<i>G. Devos, G. De Meerleer, S. Joniau</i> The role of imaging before salvage treatment of recurrent prostate cancer is controversial. Knowledge of site-specific recurrence obtained from novel imaging techniques such as prostate-specific membrane antigen-based positron emission tomography/computed tomography might provide information on the benefit of imaging before salvage therapies.		
		The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement	268
		<i>M.R. Cooperberg, P.R. Carroll, M.A. Dall'Era, B.J. Davies, J.W. Davis, S.E. Eggener, F.Y. Feng, D.W. Lin, T.M. Morgan, A.K. Morgans, D.E. Spratt, S.S. Taneja, D.F. Penson</i> We convened a multidisciplinary expert panel to make recommendations on current utility and future research needs for post-diagnosis prostate cancer biomarkers. The San Francisco Consensus Statement reflects on the rapid recent progress achieved, and the substantial work still ahead.	
		Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019	273
		<i>G. Bonkat, A. Pilatz, F. Wagenlehner</i> The 2020 European Association of Urology guidelines urological infections will reflect the European Commission restrictions on fluoroquinolone use for prophylaxis for transrectal prostate biopsy.	
Brief Correspondence		The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers	 276
	<i>E.A.M. Heijnsdijk, J. Adolfsson, A. Auvinen, M.J. Roobol, J. Hugosson, H.J. de Koning</i> The prostate cancer mortality reduction found in the European Randomized study of Screening for Prostate Cancer (ERSPC) is close to what would have been expected when all centers would have performed as the best performing center.		
	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients	280	
		<i>Y. Wei, J. Wu, W. Gu, X. Qin, B. Dai, G. Lin, H. Gan, S.J. Freedland, Y. Zhu, D. Ye</i> Germline DNA repair gene pathogenic mutation frequency is 12% in Chinese metastatic prostate cancer cases and 8.1% in high-risk localized patients. A similar prevalence was observed, although there is large disparity in the risk of prostate cancer between China and the West.	

Platinum Priorities

Review Articles and Original
Articles together with the Full
Length Editorials



Prostate Cancer

Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis EU*ACME 284

V. Kasivisvanathan, A. Stabile, J.B. Neves, F. Giganti, M. Valerio, Y. Shanmugabavan, K.D. Clement, D. Sarkar, Y. Philippou, D. Thurtle, J. Deeks, M. Emberton, Y. Takwoingi, C.M. Moore

In men with suspected prostate cancer, magnetic resonance imaging-targeted biopsy detects more clinically significant and less clinically insignificant cancer, and requires fewer cores than systematic biopsy.

Is Magnetic Resonance Imaging-targeted Biopsy Now the Standard of Care? 304

M.R. Pokorny, L.C. Thompson

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial 306

K.L. Mahon, W. Qu, H.-M. Lin, C. Spielman, D. Cain, C. Jacobs, M.R. Stockler, C.S. Higano, J.S. de Bono, K.N. Chi, S.J. Clark, L.G. Horvath

This study validates methylated Glutathione S-transferase 1 (*mGSTP1*), a novel circulating biomarker of prognosis in men with metastatic castration-resistant prostate cancer receiving docetaxel chemotherapy. The biomarker *mGSTP1* is sensitive and stable, and can be used in a routine pathology laboratory with potential value as an early surrogate endpoint and clinical decision tool.

GSTP1 as a Potential Marker of Early Chemotherapy Response for Noninvasive Detection 313

E. Izumchenko, L. Shavit Grievink, E. Rosenbaum, M.O. Hoque

The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7 315

G. Xiao, J. Yao, D. Kong, C. Ye, R. Chen, L. Li, T. Zeng, L. Wang, W. Zhang, X. Shi, T. Zhou, J. Li, Y. Wang, C.L. Xu, J. Jiang, Y. Sun

The long noncoding RNA TTTY15 promotes prostate cancer (PCa) progression by sponging let-7. Tumour growth arrest was revealed after TTTY15 knockout using the CRISPR/Cas9 system, which indicated that TTTY15 may have therapeutic implication for some PCa patients.

"Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage 327

J.R. Prensner, F.Y. Feng

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel 329

D.A. Leongamornlert, E.J. Saunders, S. Wakerell, I. Whitmore, T. Dadaev, C. Cieza-Borrella, S. Benaffif, M.N. Brook, J.L. Donovan, F.C. Hamdy, D.E. Neal, K. Muir, K. Govindasami, D.V. Conti, Z. Kote-Jarai, R.A. Eeles

This large sequencing study assessed the rate of inherited DNA repair gene mutations in prostate cancer (PCa) patients and in disease-free men. A total of 23 genes were found to be associated with PCa predisposition or the risk of aggressive disease. These findings have predictive and prognostic potential.

Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset 338

K.E. Knudsen, F.Y. Feng

Reviews



Prostate Cancer

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2 340

B. Turkbey, A.B. Rosenkrantz, M.A. Haider, A.R. Padhani, G. Villeirs, K.J. Macura, C.M. Tempany, P.L. Choyke, F. Cornud, D.J. Margolis, H.C. Thoeny, S. Verma, J. Barentsz, J.C. Weinreb

The Prostate Imaging Reporting and Data System (PI-RADS) Committee, using a consensus-based process, has recommended several modifications to PI-RADS version 2 (v2), maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category. The updated version is termed PI-RADS v2.1.

Stone Disease	Treatment of Bladder Stones in Adults and Children: A Systematic Review and Meta-analysis on Behalf of the European Association of Urology Urolithiasis Guideline Panel	 352
	<i>J.F. Donaldson, Y. Ruhayel, A. Skolarikos, S. MacLennan, Y. Yuan, R. Shepherd, K. Thomas, C. Seitz, A. Petrik, C. Türk, A. Neisius</i>	
	<p>Endoscopic treatments offer a shorter hospital stay and recovery than open surgery, with an equivalent stone-free rate (SFR). Transurethral cystolithotripsy is quicker with a continuous flow instrument and offers a shorter hospital stay compared with percutaneous cystolithotripsy. Shock wave lithotripsy appears to offer an inferior SFR.</p>	
Education	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019	368
	<i>M.-O. Grimm, A. Bex, M. De Santis, B. Ljungberg, J.W.F. Catto, M. Rouprêt, S.A. Hussain, J. Bellmunt, T. Powles, M. Wirth, H.V. Poppel</i>	
	<p>Immune checkpoint inhibitors (ICIs) are routinely used to treat advanced or metastatic urothelial and renal cell carcinoma. Here, the European Association of Urology provides recommendations to clinicians regarding how to prevent, diagnose, and clinically manage common adverse events, supporting the safe use of ICIs.</p>	
Surgery in Motion	Robot-assisted Vescica Ileale Padovana: A New Technique for Intracorporeal Bladder Replacement Reproducing Open Surgical Principles	381
	<i>G.E. Cacciamani, V. De Marco, M. Sebben, R. Rizzetto, M.A. Cerruto, A.B. Porcaro, I.S. Gill, W. Artibani</i>	
	<p>The Vescica Ileale Padovana (VIP) was first described in 1989 as a technique for total bladder replacement and gained popularity due to technical simplicity and functional advantages. Our preliminary results showed that robot-assisted VIP appears to be a feasible technique for robot-assisted totally intracorporeal bladder replacement following robotic radical cystectomy. We report the step-by-step technique of robot-assisted VIP that follows the open surgical principles of detubularization and double folding, mixing the advantages of VIP with the benefits of the robotic approach.</p>	
Original Articles	Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer	391
	<i>D.H. Moon, R.S. Basak, D.S. Usinger, G.A. Dickerson, D.E. Morris, M. Perman, M. Lim, T. Wibbelsman, J. Chang, Z. Crawford, J.R. Broughman, P.A. Godley, R.C. Chen</i>	
Prostate Cancer	<p>Patients receiving stereotactic body radiotherapy for localized prostate cancer had favorable quality of life in urinary, bowel, and sexual function domains up to 2 yr following treatment, which appeared similar to men on active surveillance.</p>	
Kidney Cancer	Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy	398
	<i>C.A. Bravi, E. Vertosick, N. Benfante, A. Tin, D. Sjoberg, A.A. Hakimi, K. Touijer, F. Montorsi, J. Eastham, P. Russo, A. Vickers</i>	
	<p>Acute kidney injury (AKI) negatively affects long-term functional recovery after partial nephrectomy and thus should be prevented. The duration of injury is informative, and should be included in the assessment of AKI and in future studies addressing this topic.</p>	
Words of Wisdom	Re: Active Surveillance of Prostate Cancer is a Viable Option in Men Younger than 60 Years	404
	<i>N. Suardi</i>	
	Re: ⁶⁸Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis	405
	<i>M. Frydenberg</i>	
	Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial	405
	<i>A. Kretschmer, D. Tilki</i>	

Research Letters

Re: Renal Cancer Surgery for Patients Without Preexisting Chronic Kidney Disease: Is There a Survival Benefit for Partial Nephrectomy?	407
<i>A. Minervini, R. Campi, A. Mari, A. Antonelli</i>	
Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial	408
<i>F. Soria, P. Gontero</i>	
Re: Rates and Predictors of Conversion to Open Surgery During Minimally Invasive Radical Cystectomy	409
<i>K.A. Guru, R.C. Sarle</i>	

The Value of Protecting Research Time During Training	411
<i>N. Singla</i>	

Letters to the Editor published online

Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105	e61
<i>Z. Mai</i>	
Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105	e63
<i>T.T. Shah, M. Peters, M. Arya, H.U. Ahmed</i>	
Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72.	e65
<i>T. Takahashi</i>	
Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?	e67
<i>B. Bhindi, C.M. Lohse, P.J. Schulte, R.J. Mason, J.C. Cheville, S.A. Boorjian, B.C. Leibovich, R.H. Thompson</i>	
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75.	e69
<i>R. Montironi, L. Cheng, M. Scarpelli, A. Cimadamore, F. Montorsi, A. Lopez-Beltran</i>	
Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?	e73
<i>A.W. Wyatt, K.N. Chi, M.E. Gleave</i>	
Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-5	e75
<i>M. Froehner, C. Thomas</i>	

Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. *Eur Urol* 2019;75:552–5 e76

S. Berg, A. Cole, Q.-D. Trinh

Re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2019.02.033> e78

B.K. Park

Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. *Eur Urol* 2019;76:329–40 e79

A.B. Rosenkrantz, B. Turkbey, J. Barentsz, J.C. Weinreb

Congress Calendar e80

The illustration on the cover of this issue is taken from the article by Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, Anwar R. Padhani, Geert Villeirs, Katarzyna J. Macura, Clare M. Tempany, Peter L. Choyke, Francois Cornud, Daniel J. Margolis, Harriet C. Thoeny, Sadhna Verma, Jelle Barentsz and Jeffrey C. Weinreb, Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2, which is published on pp. 340–351 of this issue.

